ALTIMMUNE, INC. Debt Conversion, Converted Instrument, Amount
ALTIMMUNE, INC. (ALT) reported Debt Conversion, Converted Instrument, Amount of $548.96 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-04-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2019-04-01
- ALTIMMUNE, INC. debt conversion, converted instrument, amount for the quarter ending 2017-12-31 was $0.00.
- ALTIMMUNE, INC. debt conversion, converted instrument, amount for the quarter ending 2017-09-30 was -$17.84K.
- ALTIMMUNE, INC. debt conversion, converted instrument, amount for the quarter ending 2017-06-30 was $0.00.
- ALTIMMUNE, INC. debt conversion, converted instrument, amount for the quarter ending 2017-03-31 was $566.79K.
- ALTIMMUNE, INC. debt conversion, converted instrument, amount for fiscal 2017 was $548.96K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$17.84K derived: sum of 2 quarters · filed 2019-04-01 | -$17.84K derived: sum of 3 quarters · filed 2019-04-01 | $548.96K 10-K · filed 2019-04-01 |
| 2017-09-30 | -$17.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$17.84K derived: sum of 2 quarters · filed 2018-11-13 | $548.96K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $566.79K 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $566.79K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |